{"nctId":"NCT00286091","briefTitle":"Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer","startDateStruct":{"date":"2006-01-24","type":"ACTUAL"},"conditions":["Hormone Refractory Prostate Cancer"],"count":1435,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]},{"label":"Denosumb","type":"EXPERIMENTAL","interventionNames":["Biological: Denosumab"]}],"interventions":[{"name":"Denosumab","otherNames":["XGEVAÂ®"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* men with histologically confirmed prostate cancer\n* bilateral orchiectomy at least 6 months before randomization or continuous androgen-deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) agonist or antagonist for at least 6 months before randomization\n* total testosterone level less than 50 ng/dL,\n* hormone refractory (androgen independent) prostate cancer demonstrated during continuous ADT/post-orchiectomy defined as: 3 consecutive prostate-specific antigen (PSA) values with PSA1 \\< PSA2 \\< PSA3, each PSA value must be separated by at least 2 weeks, PSA2 and PSA3 greater than or equal to 1.0 ng/mL,\n* high risk for development of bone metastasis defined as PSA value greater than or equal to 8.0 ng/mL, obtained no more than 3 months before randomization OR PSA doubling time less than or equal to 10.0 months\n\nExclusion Criteria:\n\n* prior or current evidence of radiographically detectable bone metastasis\n* known prior or current evidence of any metastatic involvement of distant organs (lymph node metastases in any region is acceptable)\n* prior or current intravenous bisphosphonate administration","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Bone Metastasis-free Survival","description":"The time to the first occurrence of bone metastasis (either symptomatic or asymptomatic) or death from any cause. Participants who did not experience bone metastasis or on-study death were censored at the last on-study contact date or the primary analysis data cutoff date, whichever came first. Median bone metastasis-free survival time was estimated using the Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"768.0","spread":null},{"groupId":"OG001","value":"897.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Bone Metastasis","description":"Time from randomization to the date of first occurrence of bone metastasis (either symptomatic or asymptomatic), excluding death. Participants who did not develop bone metastasis were censored at their last on-study bone assessment date or the primary analysis data cut-off date, whichever was first. Median time to first bone metastasis was estimated using the Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"897.0","spread":null},{"groupId":"OG001","value":"1010.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Time from randomization to the date of death. Participants who were still alive or lost to follow-up by the primary analysis data cut-off date were censored at their last contact date (on-study or during survival follow-up) or the primary analysis data cut-off date, whichever was first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1365.0","spread":null},{"groupId":"OG001","value":"1335.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":332,"n":705},"commonTop":["Back pain","Constipation","Arthralgia","Urinary tract infection","Diarrhoea"]}}}